Triple-Negative Breast Cancer Pipeline Expands with 170+ Emerging Therapies as Companies Advance Novel Treatment Approaches
核心洞察
DelveInsight's 2025 report reveals over 165 companies are developing 170+ pipeline therapies for triple-negative breast cancer (搜索), driven by rising disease prevalence and growing research investments.
Recent clinical milestones include Cardiff Oncology's positive Phase 1b data for onvansertib plus paclitaxel, Akeso (搜索)'s breakthrough therapy designation for ivonescimab combination, and multiple Phase III studies initiated by AstraZeneca and others.
Leading pipeline candidates include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), representing diverse therapeutic approaches from CDK4/6 (搜索) inhibitors to antibody-drug conjugates.
The triple-negative breast cancer (搜索) (TNBC (搜索)) therapeutic landscape is experiencing unprecedented expansion, with over 165 companies advancing 170+ investigational drugs through clinical development pipelines, according to DelveInsight's comprehensive 2025 analysis. This surge in development activity reflects the growing prevalence of TNBC and intensifying research efforts to address significant unmet medical needs in this aggressive cancer subtype.
The prevalence of triple-negative breast cancer (搜索) has been steadily increasing in recent years, resulting in a heightened need for effective treatment options. This growing patient pool, combined with expanding research and development efforts focused on innovative therapies, is expected to propel market growth. Several companies with late-stage candidates in the pipeline include Jiangsu HengRui Medicine, G1 Therapeutics, and Infinity Pharmaceuticals.
Recent Clinical Breakthroughs Drive Pipeline Momentum
Several significant clinical developments have emerged in recent months, highlighting the accelerating pace of TNBC (搜索) drug development. In November 2025, Akeso (搜索) announced that its first-in-class bispecific antibody, ivonescimab (PD-1 (搜索)/VEGF (搜索) bispecific antibody), in combination with chemotherapy for first-line treatment of TNBC has been granted Breakthrough Therapy Designation by China's National Medical Products Administration.
Cardiff Oncology reported positive data from an investigator-initiated Phase 1b clinical trial evaluating onvansertib in combination with paclitaxel in patients with metastatic TNBC (搜索) at the American Society of Clinical Oncology Annual Meeting in June 2025. The company leverages PLK1 (搜索) inhibition to develop novel therapies across a range of cancers.
Kazia Therapeutics (搜索) announced that a patient with stage IV TNBC (搜索) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab and standard chemotherapy achieved an initial immune-complete response per iRECIST criteria, suggesting a profound radiologic response in this highly aggressive metastatic cancer subtype.
Major Pharmaceutical Companies Advance Late-Stage Programs
AstraZeneca announced a Phase III study assessing the efficacy and safety of capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line treatment for patients with histologically confirmed, locally advanced or metastatic TNBC (搜索). This represents one of several late-stage programs targeting the TNBC indication.
MedSIR (搜索) announced a Phase II clinical trial designed to improve the tolerance of sacituzumab govitecan in patients with unresectable locally advanced or metastatic TNBC (搜索), refractory to at least one, and no more than two, prior standard of care chemotherapy regimens. Merck Sharp & Dohme LLC conducted a study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice in participants with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response at surgery.
Cellectar Biosciences submitted a protocol with the U.S. Food and Drug Administration for a Phase 1b dose finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC (搜索). CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, including triple negative breast, lung and colorectal cancers.
Leading Pipeline Candidates Represent Diverse Therapeutic Approaches
Trilaciclib - G1 Therapeutics
Trilaciclib is a short-acting, intravenously administered CDK4/6 (搜索) inhibitor designed to be given prior to chemotherapy. By temporarily halting cell-cycle progression, it offers two key advantages: protection of bone marrow and the immune system from chemotherapy-induced damage, and enhanced long-term immune surveillance through increased formation of specific memory T cells. The therapy is being assessed across multiple tumor types and chemotherapy regimens to evaluate its myeloprotective effects, antitumor activity, and safety when combined with cytotoxic agents and other cancer treatments. Trilaciclib is currently in Phase III development for TNBC (搜索).
Olaparib - AstraZeneca
Olaparib is an oral PARP (搜索) inhibitor developed by AstraZeneca and approved for BRCA-mutated TNBC (搜索). It acts by inhibiting PARP enzymes, thereby blocking cancer cell DNA repair, which is especially effective in tumors with BRCA1 (搜索)/2 mutations. Results from the OlympiAD trial demonstrated a significant improvement in progression-free survival compared with chemotherapy in metastatic TNBC. It is FDA-approved for germline BRCA-mutated, HER2-negative breast cancer and is also being studied in combination with immunotherapies and chemotherapies to expand its use in TNBC. The drug is currently in Phase II/III development for TNBC.
Patritumab Deruxtecan - Daiichi Sankyo/Merck
Patritumab deruxtecan (HER3 (搜索)-DXd) is an investigational HER3-targeted antibody-drug conjugate created by Daiichi Sankyo. The ADC consists of a fully human anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tumor-selective cleavable linker. As HER3 is commonly overexpressed in TNBC (搜索) and associated with poorer outcomes, this agent has shown encouraging activity in a Phase 1/2 trial involving patients with HER3-positive metastatic breast cancer. Patritumab deruxtecan is now in Phase II development for TNBC.
Market Outlook and Growth Drivers
According to DelveInsight, the TNBC (搜索) therapeutics market is expected to undergo substantial growth in the coming years, driven by a rising incidence of TNBC, improvements in diagnostic practices, increasing awareness, higher global healthcare expenditure, and the anticipated introduction of new treatment options.
Emerging TNBC (搜索) therapies include TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics), which are poised to significantly influence market expansion and transform the overall TNBC treatment landscape.
The comprehensive pipeline analysis reveals therapeutic candidates categorized across early-stage, mid-stage, and late-stage development phases, with products utilizing various routes of administration including intravenous, subcutaneous, oral, and intramuscular delivery methods. The molecular diversity spans monoclonal antibodies, small molecules, and peptides, reflecting the broad range of therapeutic approaches being pursued.
Leading companies in the TNBC (搜索) pipeline space include G1 Therapeutics, Gilead Sciences, Biotheus Inc., GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca, Jiangsu Hengrui Medicine, Novartis Pharmaceuticals, Akeso (搜索) Biopharma, Daiichi Sankyo Company/Merck, and numerous other pharmaceutical and biotechnology companies actively developing innovative treatment options for this challenging cancer indication.